Literature DB >> 22383721

Cinacalcet improves control of secondary hyperparathyroidism in peritoneal dialysis: a multicenter study.

José Portolés1, Paula López-Sánchez, María Auxiliadora Bajo, Inés Castellano, Gloria del Peso, José Ramón Rodríguez, Mayte Ribera, Almudena Ortigosa, Rafael Selgas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22383721      PMCID： PMC3525393          DOI： 10.3747/pdi.2011.00017

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN： 0896-8608            Impact factor:   1.756


× No keyword cloud information.
  10 in total

Review 1.  Meta-analysis of biochemical and patient-level effects of calcimimetic therapy.

Authors:  Giovanni F M Strippoli; Suetonia Palmer; Allison Tong; Grahame Elder; Piergiorgio Messa; Jonathan C Craig
Journal:  Am J Kidney Dis       Date:  2006-05       Impact factor: 8.860

2.  K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2003-10       Impact factor: 8.860

3.  The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients.

Authors:  Marlies Noordzij; Johanna C Korevaar; Elisabeth W Boeschoten; Friedo W Dekker; Willem J Bos; Raymond T Krediet
Journal:  Am J Kidney Dis       Date:  2005-11       Impact factor: 8.860

4.  Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.

Authors:  Geoffrey A Block; Kevin J Martin; Angel L M de Francisco; Stewart A Turner; Morrell M Avram; Michael G Suranyi; Gavril Hercz; John Cunningham; Ali K Abu-Alfa; Piergiorgio Messa; Daniel W Coyne; Francesco Locatelli; Raphael M Cohen; Pieter Evenepoel; Sharon M Moe; Albert Fournier; Johann Braun; Laura C McCary; Valter J Zani; Kurt A Olson; Tilman B Drüeke; William G Goodman
Journal:  N Engl J Med       Date:  2004-04-08       Impact factor: 91.245

5.  Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl.

Authors:  Stuart M Sprague; Pieter Evenepoel; Mario P Curzi; Maria Teresa González; Fred E Husserl; Nelson Kopyt; Lulu Ren Sterling; Chris Mix; Gordon Wong
Journal:  Clin J Am Soc Nephrol       Date:  2009-08-20       Impact factor: 8.237

6.  The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.

Authors:  Piergiorgio Messa; Fernando Macário; Magdi Yaqoob; Koen Bouman; Johann Braun; Beat von Albertini; Hans Brink; Francisco Maduell; Helmut Graf; João M Frazão; Willem Jan Bos; Vicente Torregrosa; Heikki Saha; Helmut Reichel; Martin Wilkie; Valter J Zani; Bart Molemans; Dave Carter; Francesco Locatelli
Journal:  Clin J Am Soc Nephrol       Date:  2008-01       Impact factor: 8.237

7.  KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

Authors: 
Journal:  Kidney Int Suppl       Date:  2009-08       Impact factor: 10.545

8.  Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study.

Authors:  Pablo Ureña; Stefan H Jacobson; Emanuel Zitt; Marc Vervloet; Fabio Malberti; Neil Ashman; Sean Leavey; Marianne Rix; Ingrid Os; Heikki Saha; Miroslav Ryba; Veronika Bencova; Ana Baños; Valter Zani; Denis Fouque
Journal:  Nephrol Dial Transplant       Date:  2009-04-15       Impact factor: 5.992

9.  K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients.

Authors:  F C Barreto; D V Barreto; R M A Moysés; K R Neves; M E F Canziani; S A Draibe; V Jorgetti; A B Carvalho
Journal:  Kidney Int       Date:  2008-01-09       Impact factor: 10.612

10.  Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH.

Authors:  A Torres; V Lorenzo; D Hernández; J C Rodríguez; M T Concepción; A P Rodríguez; A Hernández; E de Bonis; E Darias; J M González-Posada
Journal:  Kidney Int       Date:  1995-05       Impact factor: 10.612
  10 in total
  1 in total

1.  The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism.

Authors:  Sérgio Gardano Elias Bucharles; Fellype Carvalho Barreto; Miguel Carlos Riella
Journal:  J Bras Nefrol       Date:  2019-07-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.